Patient Cost for Osteoporosis Treatment in Postmenopausal Women
Article Sidebar
Main Article Content
Abstract
Introduction: Osteoporosis can be found in postmenopausal women and related to serious fracture and high treatment expenditure. The objective of this study was to determine cost of osteoporosis in postmenopausal women in patient perspective. Methods: A cross-sectional study was conducted in postmenopausal patients with diagnosis of osteoporosis or ICD- 10 code M80, M81 or M82 in Mahasarakham and Khon Kaen Hospital between November 2011 and February 2012. This study measured patient demographics and direct medical cost and direct non-medical cost, including food, traveling and other direct costs as well as indirect cost. Descriptive statistics were applied to summarize the costs. Results: There were 140 patients (118 outpatients and 22 inpatients) with aged 65.0 ± 9.7 years. For outpatient, average cost was 782.7 + 1,616.6 baht/visit (median cost 416.7 (20 - 15,316.7) baht/visit). Outpatient cost was mostly from direct medical cost and direct non-medical cost. For inpatient, average cost was 2,902.7 ± 4,625.6 baht/admission (median cost 859.9 (280 - 18,166.6) baht/admission). Conclusion: Osteoporosis is costly in particular inpatient services due to fractures. Therefore, prevention of osteoporotic fracture in postmenopausal women would reduce health burden and expenditure.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Chaiyasong S. Resources Required for an Expanded Program of Renal Replacement Therapy for Universal Health Care Coverage: A Case Study of Maha Sarakham and Khon Kaen. [MSc Thesis]. Khon Kean: Khon Kean University. 2005. [in Thai]
Maleewong U, Kingkaew P, Ngarmukos C, Teerawattananon Y. Cost-effectiveness and cost-utility analysis of screening and treatment strategies for postmenopausal osteoporosis. Nonthaburi: Health Technology Assessment and Intervention Program. 2007. [in Thai]
Pongchaiyakul C, Songpattanasilp T, Taechakraichana N. Burden of osteoporosis in Thailand. J Med Assoc Thai. 2008; 91 (2): 261-7.
Rattanachotpanit T, Waleekachonleort O, Chaiyasong S, Sitthithunyakit B, Chaiyasong C. Cost-effectiveness of Alendronate (Generic Price) and Risedronate(Original Price) for Prevention of Fracture in Postmenopausal Women. Nonthaburi: Health Insurance System Research Office. 2012. [in Thai]
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S. et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technology Assessment 2005; 9(22).
Tosteson ANA, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008; 14(9): 605-615.
Werayingyong P. Health Resource utilization of osteoporosis patients at Phramongkutklao hospital. [MSc Thesis]. Bangkok: Mahidol University; 2006. [in Thai]
Woratanarat P, Wajanavisit W, Lertbusayanukul W, Laohacharoensombat W, Ongphiphatanakul B. Cost analysis of osteoporotic hip fractures. J Med Assoc Thai. 2005; 88 (Suppl 5): S96-104.